UNH earnings analysis
What we found in UNH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
UnitedHealth reported Q2 2026 revenue of $112.032 billion, modestly above both Q1 2026 and Q2 2025, while diluted EPS of $6.38 declined sequentially but increased substantially year over year and exceeded consensus by $1.53. The supplied filing text does not include current-quarter gross margin, operating margin, segment results, balance-sheet balances, operating cash flow, or free cash flow, limiting assessment of earnings quality and liquidity. The 10-Q provides no new quantitative guidance and reports no material changes to the 2025 10-K risk factors; the main quantified exposure is interest-rate sensitivity, including an $8.511 billion fair-value decline in financial liabilities under a 2 percentage-point rate increase.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew sequentially and year over year
- Second-quarter revenue was $112.032 billion, up approximately 1.3% from $110.59 billion in Q1 2026 and 0.4% from $111.62 billion in Q2 2025.
- EPS remained strong year over year
- Diluted EPS was $6.38, down 7.5% from $6.90 in Q1 2026 but up 70.6% from $3.74 in Q2 2025. EPS exceeded the $4.85 consensus estimate by $1.53.
- Material share repurchases continued
- UnitedHealth repurchased 8.7 million shares during Q2 2026 at an average price of $355.37 per share; 10.6 million shares remained authorized at June 30, 2026.
- No reported control deficiencies
- Management concluded that disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected the quarter.
- Interest-rate exposure is actively managed
- The company’s interest-rate sensitivity analysis shows that a 1 percentage-point increase across the yield curve would increase annual investment income by $393 million and annual interest expense by $284 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Interest-rate fair-value volatility
- A 2 percentage-point increase in market interest rates would reduce the fair value of financial assets by $4.386 billion and financial liabilities by $8.511 billion as of June 30, 2026, creating potentially significant mark-to-market volatility.
- Capital allocation and liquidity visibility
- The filing states that the company repurchased 8.7 million shares in Q2 2026 at an average price of $355.37, including purchases under forward share-repurchase contracts settled on July 1, 2026. This represents a material use of capital while the filing does not provide current-period free cash flow or balance-sheet liquidity figures in the supplied text.
- No change to established risk profile
- The company states that there were no material changes to the risk factors disclosed in its 2025 10-K, but also notes that additional risks not currently known or deemed immaterial may adversely affect results. The filing therefore provides no reduction in the broader risk exposure despite the $6.38 quarterly EPS result.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $6.38
What they said about what is next.
The 10-Q does not provide new quantitative revenue or EPS guidance. The prior 2026 outlook of $19.50-$20.00 adjusted EPS was disclosed in the July 16, 2026 earnings release rather than updated in this filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- UnitedHealth Group reported strong Q1 2026 results, with revenues of $111.72 billion, up 2% year-over-year, and EPS of $6.90, reflecting a slight increase from $6.85 a year ago. Despite revenue growth, the company saw a…
- 10-K · March 2, 2026
- UnitedHealth’s 2025 10-K emphasizes scale across two complementary platforms — Optum (Health, Insight, Rx, Financial) and UnitedHealthcare — highlighting large membership and service footprints (e.g., Optum Health 95…
- 10-K · February 27, 2025
- UnitedHealth Group positions itself as a large, integrated health care platform centered on two complementary businesses: Optum (Health, Insight, Rx, Financial) and UnitedHealthcare (Employer & Individual, Medicare &…
- 10-Q · November 4, 2024
- UnitedHealth reported strong top-line growth for the quarter with total revenues of $100,820 million (Q3 2024), up from $92,361 million in Q3 2023, and diluted EPS of $6.51 (Q3 2024) versus $6.24 a year ago. Earnings…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing UNH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever